Wellington Management Group LLP Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Wellington Management Group LLP lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,586,605 shares of the company's stock after purchasing an additional 104,500 shares during the quarter. Wellington Management Group LLP owned about 4.73% of Nurix Therapeutics worth $67,572,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in shares of Nurix Therapeutics by 85.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock valued at $1,531,000 after purchasing an additional 31,352 shares during the last quarter. Barclays PLC boosted its position in shares of Nurix Therapeutics by 77.9% in the third quarter. Barclays PLC now owns 128,344 shares of the company's stock worth $2,884,000 after buying an additional 56,190 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after purchasing an additional 235,971 shares during the last quarter. FMR LLC raised its stake in Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after buying an additional 511,256 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Nurix Therapeutics in the 4th quarter worth approximately $1,026,000.

Nurix Therapeutics Trading Down 10.9 %

Shares of NASDAQ:NRIX traded down $1.05 during trading on Thursday, reaching $8.55. The company's stock had a trading volume of 308,977 shares, compared to its average volume of 916,099. Nurix Therapeutics, Inc. has a 12 month low of $8.52 and a 12 month high of $29.56. The firm's 50 day simple moving average is $14.42 and its two-hundred day simple moving average is $19.39. The stock has a market capitalization of $651.89 million, a PE ratio of -2.99 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million for the quarter, compared to analyst estimates of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period last year, the company posted ($0.76) earnings per share. Research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Royal Bank of Canada lifted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Wells Fargo & Company lowered their price objective on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday. HC Wainwright reissued a "buy" rating and issued a $36.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Stifel Nicolaus lowered their target price on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Needham & Company LLC cut their price objective on shares of Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.44.

Insider Transactions at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now owns 55,937 shares of the company's stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at $488,660.76. This represents a 14.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,326 shares of company stock valued at $213,449 over the last 90 days. Corporate insiders own 9.80% of the company's stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.